Matches in Wikidata for { <http://www.wikidata.org/entity/Q66032281> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q66032281 description "clinical trial" @default.
- Q66032281 description "ensayu clínicu" @default.
- Q66032281 description "klinisch onderzoek" @default.
- Q66032281 description "клінічне випробування" @default.
- Q66032281 name "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 name "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 type Item @default.
- Q66032281 label "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 label "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 prefLabel "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 prefLabel "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 P1050 Q66032281-DC056028-6C16-427F-8728-EB9D9AD73BA5 @default.
- Q66032281 P1132 Q66032281-178ABC86-3DFB-4659-A133-9DC0ABFA013F @default.
- Q66032281 P1476 Q66032281-C0487432-A640-4461-8AB7-E5B0FFC98006 @default.
- Q66032281 P17 Q66032281-64CDC97C-F3CB-43E2-9246-09324F19CAAA @default.
- Q66032281 P2899 Q66032281-EB227C73-A6EA-41DF-97D5-6334F6CC2D5B @default.
- Q66032281 P3098 Q66032281-46DB5E87-1487-451C-8511-58D33129FEC7 @default.
- Q66032281 P31 Q66032281-7CB624BD-5C66-4475-B2F5-268271325473 @default.
- Q66032281 P580 Q66032281-5239A9FD-0B06-45EB-9913-0618111346DA @default.
- Q66032281 P6099 Q66032281-DFEDDC34-6563-4C00-94E5-15C8E3C8C0D6 @default.
- Q66032281 P8363 Q66032281-6787D651-8E5C-4FC7-8D2F-5889EE82961B @default.
- Q66032281 P921 Q66032281-67AD429A-7BC3-4DC8-A589-AF6099D6A8FB @default.
- Q66032281 P1050 Q179630 @default.
- Q66032281 P1132 "+196" @default.
- Q66032281 P1476 "A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome" @default.
- Q66032281 P17 Q30 @default.
- Q66032281 P2899 "+18" @default.
- Q66032281 P3098 "NCT00092287" @default.
- Q66032281 P31 Q30612 @default.
- Q66032281 P580 "2004-07-01T00:00:00Z" @default.
- Q66032281 P6099 Q42824827 @default.
- Q66032281 P8363 Q78089383 @default.
- Q66032281 P921 Q339547 @default.